The 2024 Jury

Patricia joined Moderna in 2020 as President, General Manager to build and lead Moderna’s Canadian operations. She not only secured long-term supply agreements and ensured delivery of COVID-19 vaccines but also co-created a public-private partnership to establish a biomanufacturing facility in Canada and invest in R&D in the country. In Summer 2023, she moved to the Boston area to build and lead the global rare disease business at Moderna. She is a key member of the global commercial leadership team, leading the 2024 Commercial Build strategic initiative, in addition to her commitment to building a novel go to market model for the rare disease business around the world. 

She spent 12 years with GSK in progressively senior roles. She practiced law in a top-tier national firm (Montreal & London UK) and is a member of the Bar of Quebec. She has lived/worked in five different countries. She holds an MBA from HEC Montreal. She currently serves on the Board of Directors of AdMare BioInnovations and of the Canadian Entrepreneurs in New England (CENE) .

Cheryl is an experienced leader with a proven track record in developing strategy, driving commercial growth, and catalyzing talent excellence. She is currently an independent, Non-Executive Board Director at Allergy Therapeutics plc (LON:AGY), a pioneering immunology business with specialized focus on the research, development and commercialization of allergy treatments. She chairs the Remuneration Committee and is a member of the Audit & Risk and Nomination Committees.

Previously in the UK at ViiV Healthcare, a purpose-powered company dedicated to eradicating HIV with a mission to leave no person living with HIV behind, Cheryl set global strategy, ensuring access to medicines through a new wave of transformative medicines for the 38 million people around the world living with HIV, and modernizing the customer experience through digital engagement. Whilst in the US at GSK, Cheryl had P&L accountability >$4B USD with teams of up to 3000 employees and leadership of US operations where she drove game-changing moves that pivoted a business trajectory, launched new medicines, and surpassed external benchmarks in employee engagement. She turned around a business in crisis, returned the US business to growth, gained share, and outpaced the market. Cheryl began her pharma career at GSK in Canada with roles across Medical, Marketing and Sales, modernizing customer engagement for accelerated growth across a broad range of medicines and vaccines.   

 Cheryl holds a Degree in Pharmacy from the University of Toronto, a Masters, Business Administration from the Schulich School of Business, York University in Toronto, and executive/non-executive development from Harvard, Rotman, Wharton and Columbia.

John Helou has been is a member of the Board of Directors of Starpax Biopharma since May 2022. Priorto retirement in 2020 he was President of Pfizer Canada for eight years.  A seasoned biopharmaceuticals and biotech industry executive with over 37 years of experience.  He was Chair of the Board of Directors for Pfizer Canada and the Canadian Hospira Healthcare Corporation (following the acquisition) until retirement.  

He has led a biotech commercial Startup and managed multiple integrations, divestitures and reorganizations within Pfizer that have always focused on increased shareholder value, operational fluidity, and employee engagement. 

Throughout his tenure, Helou was known for his strategic vision in healthcare and leadership development, significantly contributing to Pfizer’s operations and patient care initiatives. He has been a strong advocate for the life sciences sector and health care delivery with government and policy makers to establish operating environments that are globally competitive in Canada.

Helou was actively involved in several industry, business, and community associations.  He was Chair and later Vice Chair to the Board of Directors of Innovative Medicines Canada (IMC), member of the Board of Directors of BIOTECanada, a member of the Business Council of Canada, as well as Chair and Board member of the Advanced Coronary Treatment (ACT) Foundation.

In 2014, he was inducted into the Marketing Hall of Fame.

He holds a Degree in Chemical Engineering from the University of Toronto.

Jamie Condie is an experienced executive in the healthcare industry, having recently retired as the President of BD (Becton, Dickinson and Company) for the USA and Canada. During his tenure, he led an organization of over 6,000 employees and was instrumental in driving both organic growth and acquisition-led expansion. Condie joined BD in 2002, initially overseeing the diabetes business, and climbed the ranks to become president of BD Canada in 2004. Before his time at BD, he held senior positions in sales, marketing, operations, and finance at several top consumer packaged goods companies, bringing a wealth of experience from both domestic and international markets.

After retiring from BD, he continues to contribute to the healthcare sector by serving on the boards of several organizations, including CareSimple and Selux Diagnostics.

He holds a Bachelor of Commerce degree from Concordia University in Montreal.